Sellas Life Sciences Group, INC Form 4 insider transactions

SELLAS Life Sciences Group reports that President and CEO Angelos M. Stergiou was granted 1,065,000 restricted stock units.

SELLAS Life Sciences Group, Inc. director John Varian received an award of 50,000 restricted stock units, vesting on December 1, 2026.

SELLAS Life Sciences Group Director Robert L. Van Nostrand received an award of 50,000 restricted stock units, vesting in December 2026.

SELLAS Life Sciences Group, Inc. Director David A. Scheinberg was awarded 50,000 restricted stock units vesting in December 2026.

SELLAS Life Sciences Group, Inc. awarded 300,000 restricted stock units to SVP, Chief Development Officer Dragan Cicic, vesting over several years.

SELLAS Life Sciences Group's CFO, John Thomas Burns, received an award of 300,000 restricted stock units, vesting over several years.

SELLAS Life Sciences Group, Inc. Director Katherine Bach Kalin received an award of 50,000 restricted stock units, vesting in December 2026.

SELLAS Life Sciences Group Director Jane Wasman received an award of 50,000 restricted stock units, vesting December 1, 2026.

SELLAS Life Sciences Group's SVP, Chief Development Officer, Dragan Cicic, had 63,800 shares withheld for tax obligations related to RSU vesting.

SELLAS Life Sciences Group CFO John Thomas Burns reported the withholding of 58,592 common shares to cover tax obligations related to RSU vesting.

SELLAS Life Sciences Group CEO Angelos M. Stergiou reported a disposition of 187,066 common shares to cover tax obligations from RSU vesting.

SELLAS Life Sciences Group Director Katherine Bach Kalin plans to acquire 63,400 shares of common stock on November 19, 2025.

SELLAS Life Sciences Group, Inc. Director Robert L. Van Nostrand reported a planned acquisition of 10,000 shares of common stock at $1.48 per share, effective June 12, 2025, under a Rule 10b5-1 plan.

Jane Wasman, a Director at SELLAS Life Sciences Group, Inc., has acquired 20,000 shares of common stock at $1.69 per share, increasing her total beneficial ownership to 30,400 shares.

Katherine Bach Kalin, a director at SELLAS Life Sciences Group, Inc., reports the acquisition and disposal of common stock on May 22, 2025.

SELLAS Life Sciences CFO John Burns was granted 194,300 restricted stock units and options to purchase 169,500 shares on January 10, 2025.

SELLAS Life Sciences CEO, Angelos M. Stergiou, was granted a significant number of restricted stock units and stock options on January 10, 2025.

David A. Scheinberg, a director at Sellas Life Sciences Group, received stock and option awards as part of his compensation.

Director Jane Wasman of SELLAS Life Sciences Group, Inc. was granted 12,500 restricted stock units and options to purchase 18,500 shares of common stock.

Robert L. Van Nostrand, a director at SELLAS Life Sciences Group, received stock awards and options as part of his compensation.

Katherine Bach Kalin, a director at SELLAS Life Sciences Group, received 12,500 restricted stock units and options to purchase 18,500 shares.

Director John Varian of SELLAS Life Sciences Group received 12,500 restricted stock units and options for 18,500 shares, according to a recent SEC filing.

Sellas Life Sciences Group's SVP, Chief Development Officer, Dragan Cicic, received a grant of restricted stock units and stock options.

Dragan Cicic, SVP and Chief Development Officer at SELLAS Life Sciences, sold 8,256 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

SELLAS Life Sciences CEO, Angelos M. Stergiou, sold 28,289 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

SELLAS Life Sciences CFO John Burns disposed of 7,165 shares of common stock to cover tax obligations related to the vesting of Restricted Stock Units.